Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tauns LaboratoriesTSE:197A -0.42%15 Receivables Turnover is 1.24 as of Dec. 2025. GuruFocus rates TSE:197A with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Tauns Laboratories ranks worse than 79.95% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Tauns Laboratories's Revenue for the
three
months ended in Dec. 2025 was 円5,908 Mil. Tauns Laboratories's average Accounts Receivable for the
three
months ended in Dec. 2025 was 円4,761 Mil.
Hence, Tauns Laboratories's Receivables Turnover for the
three
months ended in Dec. 2025 was 1.24.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tauns Laboratories Receivables Turnover Related Terms
Tauns Laboratories Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Tauns Laboratories's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:197A vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Tauns Laboratories's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tauns Laboratories Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tauns Laboratories's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tauns Laboratories (TSE:197A) has a Receivables Turnover of 1.24 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tauns Laboratories and its competitors. According to the industry distribution chart, Tauns Laboratories ranks #650 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 80%.
Is Tauns Laboratories' Receivables Turnover too high?
Tauns Laboratories' current Receivables Turnover is 1.24. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. Tauns Laboratories' value of 1.24 is 77.9% below this industry median. Based on the distribution chart, Tauns Laboratories ranks #650 out of 813 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tauns Laboratories has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tauns Laboratories ranks #650 out of 813 companies for Receivables Turnover. This places Tauns Laboratories in the lower half of its industry. The industry median Receivables Turnover is 5.60. Tauns Laboratories' value of 1.24 is 77.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tauns Laboratories's current Receivables Turnover of 1.24 is 77.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tauns Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tauns Laboratories's current Receivables Turnover is 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current Receivables Turnover of 1.24. The current Receivables Turnover is 1.24 and 77.9% below the Medical Devices & Instruments industry median of 5.60. Tauns Laboratories' overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current Receivables Turnover is 1.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
15GF Score
Get the complete analysis for TSE:197A
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:197A has been successfully added to your 
